Omeros CorpOMER

Omeros Corp filed its March quarter 10-Q this week, and the numbers land like a wet blanket. Revenue clocked in at $9.9 million, but the company still managed an operating loss of $17.4 million and burned $14.5 million in cash from operations. The one bright spot-net income of $56.1 million-was entirely a function of a $66 million gain on extinguishing debt, not the fruits of selling a single pill. Cash on hand sits at $1.9 million, while the balance sheet still carries $133.4 million in short-term investments that look increasingly like a rainy-day fund for a company that may not have many more days left to choose between trials and survival.

Omeros is a clinical-stage biotech, not a drug company-yet. Its website, filled with slick images of GPCR de-orphanisation platforms and a sprawling pipeline that includes MASP-2 inhibitor narsoplimab, PPARγ agonists, PDE10 inhibitors, and oncology bets, reads like a fundraising deck dressed up as science. The reality is that the only thing moving at speed is the cash outflow: the company spent $13.4 million on R&D in the quarter, up from a lighter burn in prior periods, while revenue remains stuck in single digits. The “next-generation therapeutics transforming patient care” tagline hasn’t yet translated into shipped product, approved label, or meaningful revenue.

The balance sheet tells the same story. Total assets were $286.2 million at March 31, but equity is negative $63.3 million, meaning the company’s liabilities exceed its tangible assets by a wide margin. Inventory is a rounding error at $183,000, which is less than the cost of a single Phase 3 patient-month in a rare-disease trial. Capital expenditures were zero in the quarter, which isn’t a sign of efficiency-it’s a sign that the company isn’t building anything material. Diluted EPS of $0.62 is a neat trick when the denominator keeps expanding: the company now has 90.1 million diluted shares outstanding, up from whatever it was the last time it issued paper to keep the lights on.

On the governance front, shareholders at the 2026 annual meeting voted to approve both the executive compensation plan and the amended Omnibus Incentive Compensation Plan-despite the company’s equity hole and cash haemorrhage. The optics are not subtle: the board is directing incentives toward a science story that hasn’t yet delivered a drug to market, while the balance sheet quietly screams dilution. The company’s website, meanwhile, still features the same polished imagery of “novel discovery,” “advanced biologics,” and “immuno-therapies,” none of which have yet produced a marketed product or meaningful revenue line.

What changed this week: nothing fundamental. The 10-Q filing is the latest public window into a company whose story outpaces its execution. The next catalyst isn’t a drug approval-it’s another capital raise or a strategic transaction to fund the burn long enough to get a product over the line. Until then, the gap between the pitch and the balance sheet is the only thing growing at a meaningful velocity.